

BIOCON BIOLOGICS PHILIPPINES INC.
BALANCE SHEET AS AT MARCH 31, 2026

(All amounts in PHP Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31,</u> <u>2026</u>	<u>March 31,</u> <u>2025</u>
ASSETS			
Non-current assets			
Financial assets			
(i) Other financial assets	3	3,081	915
Income-tax asset (net)		751	37
Total non-current assets		3,832	952
Current assets			
(i) Trade receivables	1	50,212	29,279
(i) Cash and cash equivalents	2	1,230	18,740
Other current assets	4	86	1,397
Total current assets		51,528	49,416
TOTAL		55,360	50,368
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	11,351	11,351
Other equity	6	4,721	2,587
Total equity		16,072	13,938
Current liabilities			
Financial liabilities			
(i) Trade payables	7	38,362	35,363
(ii) Other financial liabilities			
Provisions	8	300	245
Other current liabilities	9	626	822
Total current liabilities		39,288	36,430
TOTAL		55,360	50,368

BIOCON BIOLOGICS PHILIPPINES INC.**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in PHP Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Year ended March 31, 2026</u>	<u>Year ended March 31, 2025</u>
Income			
Other operating income	10	73,756	71,725
Total revenue (I)		73,756	71,725
Expenses			
Employee benefits expense	11	24,344	19,092
Other expenses	12	45,900	49,217
Total expenses (II)		70,244	68,309
Profit before tax		3,512	3,416
Tax expense			
Current tax		1,378	576
Deferred Tax		-	271
Total tax expense		1,378	847
Profit for the year		2,134	2,569

BIOCON BIOLOGICS PHILIPPINES INC.

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts in PHP Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	2,134	2,569
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Tax expense	1,378	847
Operating profit before working capital changes	3,512	3,416
Movements in working capital		
(Increase) in trade receivables	(20,933)	(23,115)
(Increase) in loans and advances and other assets	(855)	(2,277)
Increase in trade payable, other liabilities and provisions	2,858	30,256
Cash (used in)/ generated used in operations	(15,418)	8,280
Direct taxes paid	(2,092)	(891)
Net cash flow (used in)/ generated from operating activities	(17,510)	7,389
II Cash flows from investing activities		
Net cash flow (used in) investing activities	-	-
III Cash flows from financing activities		
Net cash flow generated from financing activities	-	-
IV Net (decrease)/ increase in cash and cash equivalents (I + II + III)	(17,510)	7,389
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the year	18,740	11,351
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	1,230	18,740
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	1,230	18,740
Cash on hand	-	-
	1,230	18,740
Total cash and cash equivalents [Refer note 2]	1,230	18,740

BIOCON BIOLOGICS PHILIPPINES INC.**Notes to financial statements for the year ended March 31, 2026**

(All amounts in PHP Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	50,212	29,279
	50,212	29,279
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	1,230	18,740
	1,230	18,740
3. Other non-current financial assets		
Others	3,081	915
	3,081	915
4. Other current assets		
Advance to suppliers	86	1,397
Prepayments	-	-
	86	1,397
5. Share capital		
Equity Share 1,13,510 common stock of 100 PHP each.	11,351	11,351
	11,351	11,351
6. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	2,587	18
Profit / (Loss) for the period	2,134	2,569
Net surplus/(deficit) in the statement of profit and loss	4,721	2,587
Total other equity	4,721	2,587
7. Trade payables	38,362	35,363
8. Provisions		
Current		
Compensated absences	300	245
	300	245
9. Other liabilities		
Current liabilities		
Statutory liabilities	626	822
	626	822

BIOCON BIOLOGICS PHILIPPINES INC.**Notes to financial statements for the year ended March 31, 2026**

(All amounts in PHP Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
10. Other operating income		
Support service cross charge to Group Companies	73,756	71,725
	73,756	71,725
11. Employee benefits expense		
Salaries, wages and bonus	24,271	18,996
Employee stock compensation expense	-	96
Staff welfare expenses	73	-
	24,344	19,092
12. Other expenses		
Rates and taxes	1,798	1,416
Rent	4,022	3,732
Legal and professional fees	6,408	12,695
Travelling and conveyance	22,008	9,549
Sales promotion expenses	15,845	18,511
Printing and stationery	2,172	254
Communication expenses	172	57
Foreign exchange loss/(gain) net	(7,669)	5
Miscellaneous expenses	890	1,427
Insurance Charges	254	1,570
	45,900	49,217